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Background Zinc supplementation for the treatment of diarrhoea has been
shown to decrease the duration and severity of the diarrhoeal epi-
sode, diarrhoea hospitalization rates and, in some studies, all-cause
mortality. Using multiple outcome measures, we sought to estimate
the effect of zinc for the treatment of diarrhoea on diarrhoea mor-
tality and subsequent pneumonia mortality.
Methods We conducted a systematic review of efficacy and effectiveness
studies. We used a standardized abstraction and grading format
and performed meta-analyses for all outcomes with 52 data
points. The estimated effect on diarrhoea mortality was determined
by applying the standard Child Health Epidemiology Reference
Group rules for multiple outcomes.
Results We identified 13 studies for abstraction. Zinc supplementation
decreased the proportion of diarrhoeal episodes which lasted
beyond 7 days, risk of hospitalization, all-cause mortality and diar-
rhoea mortality. Using diarrhoea hospitalizations as the closest and
most conservative possible proxy for diarrhoea mortality, zinc for
the treatment of diarrhoea is estimated to decrease diarrhoea mor-
tality by 23%.
Conclusion Zinc is an effective therapy for diarrhoea and will decrease diar-
rhoea morbidity and mortality when introduced and scaled-up in
low-income countries.
Keywords Diarrhoea, mortality, treatment, zinc
Background
Zinc for the treatment of diarrhoea has been recom-
mended by the World Health Organization (WHO)
and United Nations Children’s Fund (UNICEF) since
2004,
1 yet access to this essential treatment remains
limited. When given for 10–14 days during and fol-
lowing the diarrhoeal episode, zinc has been shown to
decrease the duration and severity of the episode,
2
as well as decrease the incidence of diarrhoea and
pneumonia episodes in the subsequent 2–3 months.
3
Early studies that found a reduction in the duration
and severity of the episode were conducted in diar-
rhoea treatment clinics and inpatient settings.
4 In
later large-scale studies, investigators randomized
entire communities to include zinc in addition to
oral rehydration solution (ORS) or ORS alone
5,6 and
observed similar effects on diarrhoea duration,
pneumonia incidence as well as reductions in hospi-
talizations and mortality that smaller individually
randomized controlled trials (RCTs) had not been
designed to detect.
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i63Very few studies have been designed or powered to
detect differences in all-cause mortality or diarrhoea-
specific mortality. Although cause-specific mortality
data are the ideal when estimating the possible
effect of an intervention on saving lives, for diarrhoea,
there are additional outcomes which can serve as ade-
quate proxies, such as hospitalization and prolonged
diarrhoea.
7,8 Diarrhoea treated promptly in the home
to prevent and treat dehydration rarely becomes
lethal; therefore, by including outcomes such as diar-
rhoea hospitalizations and episodes lasting beyond
7 days, we are able to focus on the episodes which
are more severe and thus far more likely to result in
death.
This systematic review of the effect of zinc for diar-
rhoea treatment has been designed to meet the needs
of the Lives Saved Tool (LiST) and has therefore been
designed differently than the previously published
traditional systematic reviews.
9–11 In LiST, increases
in coverage of an intervention result in a reduction
of one or more causes of mortality. Therefore, the
systematic review and methods presented here, as
well as the GRADE process as outlined in this journal
supplement,
12 were designed to develop estimates of
the effect of an intervention in reducing death due to
diarrhoea.
Together with low-osmolarity ORS and continued
feeding, zinc promises to reduce diarrhoea morbidity
and mortality and have additional benefits on pneu-
monia morbidity and mortality in the 2–3 months
following treatment.
13,14 Although there have been
numerous systematic reviews and meta-analyses sum-
marizing the effect of zinc supplementation,
2,3,15,16
none have considered the effect of zinc when given
as diarrhoea therapy on diarrhoea mortality. Here we
present the evidence supporting this claim as well as
the evidence suggesting a reduction in subsequent
diarrhoea episodes.
Methods
We systematically reviewed all published literature
from 1990 to 2009 to identify studies of zinc supple-
mentation for the treatment of acute and persistent
diarrhoea amongst children younger than 5 years of
age. As per the Child Health Epidemiology Reference
Group (CHERG) systematic review guidelines,
12 we
searched PubMed, Cochrane Libraries and all WHO
regional databases and included publications in
every language available in these databases. The ini-
tial searches were conducted on 31 January 2009 and
updated on 15 October 2009. We used the Medical
Subject Heading Terms (MeSH) and keywords-search
strategies using various combinations of: zinc, treat-
ment, and diarrhoea. Every effort was made to gather
unpublished data when reports were available for full
abstraction. Studies were included if data from one of
the following outcomes was provided: all-cause
mortality, diarrhoea mortality, diarrhoea hospitaliza-
tions, pneumonia hospitalizations, prolonged diar-
rhoea (episode lasting 47 days), diarrhoea and
pneumonia incidence in the period up to 3 months
following treatment. All outcome measures to be
included were determined a priori.
Inclusion/exclusion criteria
We limited the search to RCT studies conducted in
low- and middle-income countries (LMICs) where
zinc was given as a diarrhoea treatment for
57 days to infants and children between 1 and
59 months of age.
17 Studies were included if zinc
was given alone or in combination with vitamins.
Studies that provided iron were excluded because
iron is known to interfere with zinc absorption and
iron-containing formulations are not recommended
for the treatment of diarrhea.
18 All included studies
contained a placebo or a suitable control group that
was identical to the experimental group, except that it
did not contain zinc. Studies conducted ‘solely’ in spe-
cial populations (i.e. only cholera patients, etc.) were
excluded. The zinc dose in included studies was
between 10 and 40mg/day which is in line with the
WHO 2004 recommendation of 20mg/day for 6–59
months and 10mg/day for 1–5 months.
1 Acceptable
formulations included syrups and tablets. Studies of
zinc-fortified ORS were excluded because the zinc
dose does not meet WHO guidelines for daily dose
or minimal treatment days.
Abstraction, analyses and summary measures
All studies which met final inclusion and exclusion
criteria were double-data abstracted into a standar-
dized form for each outcome of interest.
12 We
abstracted key variables with regard to the study
identifiers and context, study design and limitations,
intervention specifics and outcome effects. Each study
was assessed and graded according to the CHERG
adaptation of the GRADE technique.
19 Studies
received an initial score of high if they were RCTs
or cluster-RCTs (cRCTs). The grade was decreased
one grade for each study-design limitation. In addi-
tion, studies reporting an intent-to-treat analysis or
with statistically significant strong levels of associa-
tion (480% reduction) received 0.5–1.0 grade increase.
Any study with a final grade of very low was excluded
on the basis of inadequate study quality.
For any outcome with more than one study we
conducted a meta-analysis and reported the
Mantel–Haenszel pooled relative risk and correspond-
ing 95% confidence interval (CI) or the DerSimonian–
Laird pooled relative risk and corresponding 95% CI
where there was unexplained heterogeneity such
as major differences in study design.
12 All analyses
were conducted using STATA 9.0 statistical
software.
20
i64 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYWe summarized the evidence based on outcome by
including assessment of the study quality and quan-
titative measures according to standard guidelines
12
for each outcome. For the outcome of interest,
namely the effect of zinc for the treatment of diar-
rhoea on the reduction of diarrhoea mortality, we
applied the CHERG Rules for Evidence Review
12 to
the collective diarrhoea morbidity and mortality out-
comes to generate a final estimate for reduction in
diarrhoea mortality and pneumonia mortality.
Results
We identified 251 titles from searches conducted in all
databases (Figure 1). After initial screening of titles
and abstracts we reviewed 35 papers for the identified
outcome measures of interest and included 13 papers
in the final database. To estimate the effect of zinc for
diarrhoea treatment on diarrhoea mortality, we found
four studies which reported data on all-cause mortal-
ity,
4,5,21,22 one study which reported diarrhoea-specific
mortality rates,
5 two studies which reported diarrhoea
hospitalization rates
5,6 and seven studies which
reported data on prolonged diarrhoea (57 days)
23–29
(Supplementary Table 1). To estimate the effect of
zinc for diarrhoea treatment on diarrhoea incidence,
we found three studies which reported data on diar-
rhoea incidence.
5,6,21 To estimate the effect of zinc for
diarrhoea treatment on pneumonia morbidity and
mortality in the months following treatment, we
found one study which reported data on pneumonia
mortality,
5 two studies which reported data on pneu-
monia hospitalizations
5,6 and three studies which
reported data on pneumonia point prevalence.
5,6,21
All abstracted studies were either blinded, randomized
controlled treatment trials or cluster-randomized
intervention trials. There were very few limitations
based on study design and execution; one study
included infants 1–5 months of age,
21,25 one study
had <6 clusters per study arm
6 and several studies
included daily zinc doses less than the WHO recom-
mendation for children 56 months.
23,24,28,29
In Table 1 we report the quality assessment of stu-
dies by outcome, as well as results from correspond-
ing meta-analyses. Of the four outcomes related to
diarrhoea mortality, the effect size ranged from 23%
(Figure 2) for diarrhoea hospitalizations to 66% for
diarrhoea mortality.
5 We applied the CHERG Rules
for Evidence Review to these four outcomes.
Figure 1 Synthesis of study identification in review of the effects of zinc for the treatment of diarrhoea on all-cause
mortality, diarrhoea mortality, diarrhoea hospitalization and prolonged diarrhoea. (Final number of papers reported by
outcome; thus one paper may be counted for more than one outcome).
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i66 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYBecause diarrhoea mortality data were limited (fewer
than 50 deaths) we used a severe morbidity outcome
to estimate the effect on mortality. The two large
cRCTs reported a 23% difference in hospitalization
rates for 4300 hospitalizations (Figure 3).
There are two large-scale studies among children of
all ages and one smaller study among infants 1–5
months of age which demonstrated that zinc given
as a treatment for diarrhoea may decrease diarrhoea
prevalence by 19% and the prevalence of severe acute
lower respiratory infection (ALRI)/pneumonia epi-
sodes in the months following supplementation by
23%.
5,6,21 In addition, the two large-scale effectiveness
studies found that the introduction of zinc led to a
decrease of pneumonia hospitalizations by 50%.
However, these estimates are not statistically signifi-
cant and thus, at this point in time, it is not possible
to conclude that there is an evidence of benefit.
Conclusions
Diarrhoea remains the second leading cause of death
among children under 5 in the developing world.
30 In
our systematic review, 11 of the 13 studies we identi-
fied reported results suggesting a benefit of zinc on
severe diarrhoea morbidity and mortality outcomes.
Applying the CHERG Rules for Evidence Review to
reviewed studies and assessment of multiple morbid-
ity and mortality outcomes, we estimate that zinc for
the treatment of diarrhoea will reduce diarrhoea mor-
tality by 23%. With 41000 hospitalizations, there is
less uncertainty in the effect of zinc on this outcome
as compared to the mortality outcomes. In addition,
the effect size associated with diarrhoea hospitaliza-
tions (23% reduction) is more conservative than the
observed reduction in all-cause or cause-specific mor-
tality and prolonged diarrhoea as observed in similar
studies.
5,6 Because all estimates are consistent, this
increases confidence that 23% is a realistic estimate
for a reduction in mortality that we would expect to
observe when scaling up zinc for the treatment of
diarrhoea.
Because this estimate was not derived solely from
mortality data, it has some limitations. The two large
cRCTs,
5,6 which contributed the hospitalization data
were effectiveness studies; therefore, coverage was
not 100%. Although coverage did reach relatively
high levels (480% in Bangladesh within 7 months),
there were no adjustments made to the results to
account for the <100% coverage rates which would
make the effect estimates conservative. However, it
could also be argued that these were still in fact stu-
dies and thus countries rolling out programmes in
larger communities may not achieve the same effect
because of poorer compliance, insufficient training of
health-care providers or other implementation
obstacles.
One additional limitation is the inability to comple-
tely separate the effect of zinc from the effect of ORS
in the large-scale effectiveness trials. In these studies
the introduction of zinc also increased ORS-use rates
in the intervention communities. Although program-
matically ideal, it is not possible to separate the effect
of zinc from the effect of ORS on diarrhoea hospital-
ization and mortality. However, in the six studies we
reviewed, zinc decreased prolonged diarrhoea by 33%.
This estimate is generated from blinded trials where
ORS use was constant in the zinc and control groups
and thus the zinc effect more accurately represents
the added benefit of zinc supplementation. For these
reasons the 23% reduction would not appear to over-
estimate the effect of zinc on diarrhoea mortality.
In addition to the effect on the duration and severity
of the treated episode, zinc has been shown to
decrease diarrhoea prevalence in both 24-h and
2-week recall surveys. Although in our review we
found a 19% reduction in diarrhoea prevalence fol-
lowing the treated episode, the large-scale studies
from which the weight of this pooled estimate is
derived did not conduct prevalence surveys solely
among children receiving zinc vs those not receiving
zinc. This effect would logically be greater than
that measured simply in all children residing in com-
munities where zinc was available. Thus, the 19%
reduction could be a conservative estimate of the
Baqui et al, 2002
Bhandari et al, 2008
Pooled
0 0.25 0.5 0.75 1 1.25 1.5 1.75
Relative Risk (95% Confidence Interval)
2
Figure 2 Forest plot for the effect of zinc for the treatment
of diarrhoea on diarrhoea hospitalizations.
Prolonged Diarrhea (n=7; 768 events)
Zn reduces prolonged diarrhea by 25% (-9-51%)
Rule 3:  APPLY
High evidence of morbidity reduction and low evidence
for mortality reduction: Highly plausible  
Diarrhea Mortality (n=1; 12 events)
Zn reduces mortality by 66% (95% CI:  -37-96%)
Rule 1:  Do not apply
< 50 events 
All cause mortality (n=4;  61 events)
Zn reduces mortality by 46% (12-68%)
Rule 2:  Do not apply
> 50 events but low quality
Diarrhea Hospitalizations (n=2; 1367 events) 
Zn reduces diarrhea hospitalizations 
by 23% (15-31%)
Possible Outcome 
Measures
Application of 
Standard  Rules
Figure 3 Application of standardized rules for choice of
final outcome to estimate effect of zinc on the reduction
of diarrhoea mortality.
ZINC FOR THE TREATMENT OF DIARRHOEA i67preventive benefits on diarrhoea prevalence. Some
studies have found that when used as a diarrhoea
treatment, zinc also has a preventive effect on
future pneumonia morbidity and mortality but these
effects are not statistically significant; therefore,
definitive conclusions with regard to an effect size
cannot be made at this time.
Zinc supplementation has been proven to decrease
diarrhoea morbidity and mortality and is currently
recommended as an adjunct treatment for all diar-
rhoea episodes.
1 The methods by which we derived
a specific effect on diarrhoea mortality are novel,
involve multiple outcomes and are inherently based
on limitations in available data. Some will challenge
the notion that providing an estimate for an effect on
mortality based on anything but RCTs with mortality
as an outcome should not be done. However, because
of the strength of the evidence supporting zinc for
diarrhoea treatment, RCTs are no longer ethical;
thus the ideal data will likely not be available.
The methods and results we propose in this article
are transparent and provide a conservative and com-
parable estimated effect size of zinc for the treatment
of diarrhoea on diarrhoea mortality. Zinc for the treat-
ment of diarrhoea is an important child-survival
intervention and, in combination with ORS, is key
for a reduction in overall child mortality.
Supplementary data
Supplementary data are available at IJE online.
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KEY MESSAGES
 The evidence supporting zinc for the treatment of diarrhoea includes 12 high-quality randomized
efficacy and effectiveness trials with demonstrated reductions in severe morbidity and mortality.
 Zinc for the treatment of diarrhoea reduces diarrhoea mortality by 23%.
 When given as diarrhoea treatment, zinc supplementation not only decreases the severity of the
initial episode, but may prevent future diarrhoeal episodes in the 2–3 months following
supplementation.
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